Last reviewed · How we verify

NCT05221788

Effect of Goal-directed Hemodynamic Therapy on Short-term Postoperative Complications in Patients With Extensive Burns

Completed NA Last updated 3 February 2022
What this trial tests

NA trial testing Goal-directed hemodynamic therapy in Hemodynamics in 100 participants. Completed in 1 December 2021.

Timeline
1 January 2020
Primary endpoint
1 December 2021
1 December 2021

Quick facts

Lead sponsorGuangzhou Red Cross Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposesupportive care
Enrollment100
Start date1 January 2020
Primary completion1 December 2021
Estimated completion1 December 2021
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Guangzhou Red Cross Hospital

Who can join

Adults 18 to 65, any sex, with Hemodynamics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To investigate the effect of goal-directed hemodynamic management on perfusion and short-term prognosis of patients undergoing scab grafting in early stage of extensive burns.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effect Of Goal-Directed Haemodynamic Therapy On Short-Term Postoperative Complications In Patients With Extensive Burns: A Single-Centre Randomised Controlled Trial
    Liang B, Cai L, Cao Y, Huang H, et al · · 2022 · DOI 10.21203/rs.3.rs-1341626/v1

Verify or expand the search:

Other trials of Goal-directed hemodynamic therapy

Trials testing the same drug.

Other recruiting trials for Hemodynamics

Currently open trials in the same condition.

Other Guangzhou Red Cross Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05221788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing